Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study

Autor: Louise Baucher, Virginie Lemiale, Adrien Joseph, Florent Wallet, Marc Pineton de Chambrun, Alexis Ferré, Romain Lombardi, Laura Platon, Adrien Contejean, Charline Fuseau, Laure Calvet, Frédéric Pène, Achille Kouatchet, Djamel Mokart, Elie Azoulay, Antoine Lafarge

Publikováno v: Annals of Intensive Care, Vol 13, Iss 1, Pp 1-11 (2023)

Abstract Background In the last decade, Ibrutinib has become the standard of care in the treatment of several lymphoproliferative diseases such as chronic lymphocytic leukemia (CLL) and several non-Hodgkin lymphoma. Beyond Bruton tyrosine kinase inhi

Externí odkaz: https://doaj.org/article/88ab80d8376f4cbb88ddc2f3b3de0256

Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study

Autor: Philippe Zimmermann, Hélène Gros, Arezki Oufella, Helene Guillot, Lee S. Nguyen, Louise Baucher, Louis Dubret, Faiza Boucenna, Paul Barsoum, Benjamin Rossi, Marie Anne Bouldouyre, Yves Allenbach, Joe-Elie Salem

Publikováno v: Pharmaceuticals
Pharmaceuticals, Vol 13, Iss 317, p 317 (2020)
Pharmaceuticals, MDPI, 2020, 13 (10), pp.317. ⟨10.3390/ph13100317⟩
Volume 13
Issue 10

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted for severe COVID-19 pneumonia (SpO2 &le
96% despite O2-support &

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa1a955481c99889adb1ec2bf11b761a
https://pubmed.ncbi.nlm.nih.gov/33080877